|
Congestive heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In addition, the levels of IL-6, TNF-α and IL-1β decreased to 154.41 ± 7.72 pg/mg protein, 110.02 ± 6.96 pg/mg protein and 39.39 ± 5.27 pg/mg protein, respectively; the relative activity of p38 MAPK decreased to 2.60 ± 0.40 in CHF + SOJ group.
|
30860934 |
2019 |
|
Congestive heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Inflammasome activation and IL-1β secretion are implicated in myocardial infarction (MI) and resultant heart failure; however, little is known about how macrophage lysosomes regulate these processes.
|
31672943 |
2019 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
These randomized double-blind placebo-controlled data suggest that therapy with canakinumab, an interleukin-1β inhibitor, is related to a dose-dependent reduction in HHF and the composite of HHF or heart failure-related mortality in a population of patients with prior myocardial infarction and elevations in high-sensitivity C-reactive protein.
|
30586730 |
2019 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cardiac resynchronization therapy reduces expression of inflammation-promoting genes related to interleukin-1β in heart failure.
|
31612215 |
2019 |
|
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Compared with those who took no IL-1 blockage, patients taking IL-1 blockage experienced a decreased risk of overall MACE (RR 0.88, 95% CI 0.82-0.94), unstable angina (RR 0.80, 95% CI 0.66-0.98), and breakthrough or recurrence of heart failure (RR 0.44, 95% CI 0.22-0.87).
|
31415103 |
2019 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
The multivariable logistic regression showed that IL-1β [relative ratio (RR) = 1.08, 95% CI: 1.02-1.15, <i>P</i> = 0.010], IL-6 (RR = 1.03, 95% CI: 1.01-1.06, <i>P</i> = 0.016), PTX-3 (RR = 1.31, 95% CI: 1.11-1.55, <i>P</i> = 0.001), and ANGPTL-4 (RR = 1.05, 95% CI: 1.02-1.07, <i>P</i> < 0.001) were independently associated with HF, while IL-6 (RR = 1.03, 95% CI: 1.01-1.04, <i>P</i> = 0.019), PTX-3 (RR = 1.23, 95% CI: 1.06-1.43, <i>P</i> = 0.007), and ANGPTL-4 (RR = 1.03, 95% CI: 1.01-1.06, <i>P</i> = 0.005) were independently associated with the HF subtype.
|
31105751 |
2019 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Most advanced are clinical studies with IL-1 antagonists showing improved β-cell function and glycemia and prevention of cardiovascular diseases and heart failure.
|
31127805 |
2019 |
|
Congestive heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Expression levels of IL-1ß, IL-6, TNF-alpha, and BAX mRNA were significantly associated with the degree of CHF.
|
30968846 |
2019 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interleukin-1 (IL-1) is a pro-inflammatory cytokine released during AMI and involved in adverse remodeling and heart failure (HF).
|
30033595 |
2018 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interestingly, interfering with IL-1 has proved to be also effective in other cardiovascular manifestations, such as myocarditis, arrhythmias, and heart failure.
|
29904899 |
2018 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
The promising results of phase II clinical trials of IL-1 blockade in patients with acute myocardial infarction and heart failure have been followed by a successful phase III trial in patients with prior acute myocardial infarction.
|
29549570 |
2018 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immunomodulatory interventions in myocardial infarction and heart failure: a systematic review of clinical trials and meta-analysis of IL-1 inhibition.
|
30010800 |
2018 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Phase II studies in patients with HF show improved exercise capacity with IL-1 blockade.
|
29584915 |
2018 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to examine the effects of exercise on changes in ASC methylation and activation of the IL-1 family cytokine IL-1β in persons with HF.
|
29683921 |
2018 |
|
Congestive heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
IL-1β could induce expression of sST2, accelerating the progression of heart failure after acute MI.
|
29565745 |
2018 |
|
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These data suggest that individuals with TET2-mediated clonal hematopoiesis may be at greater risk of developing heart failure and respond better to IL-1β-NLRP3 inflammasome inhibition.
|
29471939 |
2018 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
These studies demonstrate that circulating IL-1β, which increases in cardiovascular disorders such as hypertension and heart failure, acts on the SFO to increase inflammation and RAS activity in the SFO and PVN and that intervening in these neurochemical processes in the SFO can significantly reduce the sympathetic response.
|
29167166 |
2018 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
We thus evaluated treatment with the IL-1 receptor antagonist anakinra in a case of heart failure secondary to fulminant myocarditis.
|
28232838 |
2017 |
|
Congestive heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Mean percent ASC methylation and plasma IL-1β levels are associated with clinically meaningful differences in V˙O2peak in persons with HF.
|
28072632 |
2017 |
|
Congestive heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Activation of hypothalamic OXT neurons to elevate parasympathetic tone reduced cellular hypertrophy, levels of IL-1β, and fibrosis during TAC-induced HF in rats.
|
28472396 |
2017 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
We hypothesized that administration of IL-1 (interleukin-1) receptor antagonist (anakinra) could inhibit the inflammatory response and improve peak aerobic exercise capacity in patients with recently decompensated systolic HF.
|
29141858 |
2017 |
|
Congestive heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
IL-1β levels may be useful for the evaluation of diagnosis in acutely decompensated HF.
|
29182005 |
2017 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recombinant human IL-18-binding protein (IL-18BP) or an IL-18-blocking antibody (IL-18AB) was used to neutralize endogenous IL-18 after challenge with the plasma of patients with HF or with recombinant murine IL-1β in adult male mice.
|
24531812 |
2014 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
In contrast, IL1β is a strong promoter of interstitial collagen remodeling that may contribute to ventricular dilation and heart failure in the ischemic myocardium.
|
24247107 |
2013 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Besides this, the influence of mental stress on heart failure is poorly documented despite its effects on sympathetic stimulation of interleukin-1β (IL-1β) secretion.
|
21811191 |
2011 |